1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. Aker BioMarine AS
  6. News
  7. Summary
    AKBM   NO0010886625


Real-time Oslo Bors  -  05/18 10:25:17 am EDT
48.35 NOK   +1.04%
05/05UNIVERSITY OF GLASGOW : Krill oil may be beneficial to muscle function and size, in people over 65
04/29Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2022
04/29Aker BioMarine - first quarter 2022
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Aker BioMarine appoints new EVP for Human Health & Nutrition business area

01/17/2022 | 04:12am EDT
17 January 2022. Simon Seward has been appointed EVP of Human Health & Nutrition
in Aker BioMarine ASA from today. He is an industry leader with broad experience
from the nutraceutical and aquaculture sectors.

Seward will lead the company's ambitious growth strategy for the Superba brand.
He began working for Aker BioMarine in 2019 with the responsibility to grow
QRILL Aqua sales in Asia and subsequently to lead global sales to the
aquaculture sector.

"We are excited to welcome Simon as leader of our Human Health and Nutrition
business. During his three years with us, he has proven that he is a capable
leader and a valuable asset to our team. Simon will play a key role in the
execution of our ambitious accelerated growth plan for Superba krill oil, said
Matts Johansen, CEO of Aker BioMarine".

"I am looking forward to leading the Superba team and bringing continued success
to our key markets in the Americas, Asia and Europe, said Simon Seward. "We have
high growth ambitions and compelling commercial strategies for Superba krill oil
over the next few years. By 2025, we are aiming to double our topline and I am
committed to lead the team to accomplish this goal."

With three decades of international sales and marketing experience across a
number of sectors, including the global nutrition and aquaculture markets for
the last ten years, Seward brings an in-depth knowledge base of the global B2B
nutritional market to his new position. Prior to working at Aker BioMarine,
Seward worked with the Norwegian human nutrition group, Sana Pharma Holding, in
a variety of management roles including the launch of the Algaliff astaxanthin

As EVP of Human Health & Nutrition, he will report to CEO Matts Johansen, who
temporarily held the position.

For further information, please contact:
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com

About Superba krill oil
Superba krill oil is extracted from the Antarctic krill and is an efficient
delivery form of vital nutrients such as choline and omega-3s. It offers a range
of health benefits to match the needs of health-conscious consumers, and the
possibilities are limitless for our customers. Powered by phospholipids, Superba
Krill ensures that omega-3s EPA & DHA and choline are delivered to parts of the
body that need them the most, such as the brain, heart, eyes and liver. 

About Aker BioMarine
Aker BioMarine is an Antarctic krill-harvesting company and leading biotech
innovator developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange

Stocks mentioned in the article
ChangeLast1st jan.
AKER BIOMARINE AS 1.04% 48.35 Real-time Quote.-10.96%
HUMAN HEALTH HOLDINGS LIMITED -1.26% 1.57 Delayed Quote.31.41%
All news about AKER BIOMARINE AS
05/05UNIVERSITY OF GLASGOW : Krill oil may be beneficial to muscle function and size, in people..
04/29Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2022
04/29Aker BioMarine - first quarter 2022
04/21Aker BioMarine ASA - Invitation to presentation of the first quarter 2022 results
04/20Aker BioMarine ASA - Minutes of Annual General Meeting 2022
04/20Aker Biomarine AS Announces Board Changes
04/01AKER BIOMARINE : joins Innovation Norway and Aker ASA initiative to accelerate the green t..
03/31AKER BIOMARINE : PDF - Proxy Form AGM 2022
03/29AKER BIOMARINE : PDF - Notice of the Annual General Meeting 2022
03/29AKER BIOMARINE : PDF - Recommendation selection of Auditor
More news
Sales 2022 3 036 M 310 M 310 M
Net income 2022 10,9 M 1,11 M 1,11 M
Net Debt 2022 2 925 M 298 M 298 M
P/E ratio 2022 366x
Yield 2022 -
Capitalization 4 237 M 432 M 432 M
EV / Sales 2022 2,36x
EV / Sales 2023 1,97x
Nbr of Employees 429
Free-Float 18,6%
Duration : Period :
Aker BioMarine AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKER BIOMARINE AS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 4,93 $
Average target price 6,11 $
Spread / Average Target 24,0%
EPS Revisions
Managers and Directors
Matts Eirik Johansen Chief Operating Officer
Katrine Mourud Klaveness Chief Financial Officer
Ola Sn°ve Chairman
Sindre Skjong Technical Director
Trond Atle Smedsrud Executive Vice President-Strategic Investments
Sector and Competitors
1st jan.Capi. (M$)
KWS SAAT SE & CO. KGAA-16.44%2 168
BAYWA AG28.16%1 800
THE ANDERSONS, INC.-0.26%1 291